Media ReleasesSUDA Pharmaceuticals

View All SUDA Pharmaceuticals News

SUDA Pharmaceuticals - ZolpiMist Update

SUDA Pharmaceuticals Ltd (ASX: SUD), a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system, advises that Mitsubishi Tanabe Pharma Korea (MTPK) have indicated their intention not to proceed with the License and Supply Agreement for ZolpiMist.

MTPK cited challenges with their regulatory body, the Ministry of Food and Drug Safety (MFDS). SUDA has agreed to terminate the Agreement and the Company notes that there is no immediate financial impact as a result of the termination. SUDA will continue to focus on its partnership with TEVA, and look to secure additional partners for the ASEAN region and other territories. 

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.